Last updated on February 2018

Radotinib as 3rd or Later Line Therapy in CP-CML


Brief description of study

The purpose of this study is to determine whether radotinib is effective and safe for patients with chronic myeloid leukemia, chronic phase who are intolerable or resistant to prior 2 or more tyrosine kinase inhibitors.

Detailed Study Description

The purpose of this study is to determine whether radotinib 400mg bid is effective and safe for patients with chronic myeloid leukemia, chronic phase who are intolerable or resistant to prior 2 or more tyrosine kinase inhibitors. The primary end point is major cytogenetic response by 12 months.

Clinical Study Identifier: NCT02422719

Contact Investigators or Research Sites near you

Start Over

Hawk Kim, M.D., Ph.D.

Ulsan University Hospital
Ulsan, Korea, Republic of
  Connect »